1. Kodiak Soars on Phase 3 Success for Diabetic Retinopathy Drug KSI-301
Kodiak Sciences Inc. (KOD) stock surged after the biotech company announced its lead candidate, KSI-301, met its primary endpoint in a pivotal Phase 3 trial for diabetic retinopathy. The positive topline results from the GLEAM study mark a critical inflection point, demonstrating the antibody biopolymer conjugate's pot...